Precipio Announces Preliminary Q1 2018 Year-over-Year Revenue Increase of 286%
Growth resulting from commercial team reorganization, product and service cross-selling, and increased business stabilization
NEW HAVEN, Conn., May 14, 2018 -- Specialty diagnostics company Precipio, Inc.(NASDAQ:PRPO), announces preliminary, unaudited 1st quarter 2018 revenues of approximately $712,000, representing a 286% increase from the same quarter in the prior year.
Drivers of revenue growth that have been completed in Q1 2018 include:
a restructured and expanded sales staff, including a new VP of sales, and sales reps with years of directly relevant industry sales experience
dedication of separate sales infrastructure to pathology services and ICE COLD PCR™ (ICP) / Pharma projects
increased cross-selling of pathology services with ICP lung cancer treatment resistance panel as well as others
- Published: 14 May 2018
- Written by Editor